NVOS (Novo Integrated Sciences) Debt-to-Equity: 0.45 (As of May. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVOS Novo Integrated Sciences Inc NVOS
12 GF Score
Price $0.00
View Full Analysis

What is Novo Integrated Sciences Debt-to-Equity?

Novo Integrated Sciences NVOS -84.62% 12 Debt-to-Equity is 0.45 as of May. 2024. GuruFocus rates NVOS with a GF Score™ of 12/100.

Novo Integrated Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was $2.90 Mil. Novo Integrated Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was $1.60 Mil. Novo Integrated Sciences's Total Stockholders Equity for the quarter that ended in May. 2024 was $9.96 Mil. Novo Integrated Sciences's debt to equity for the quarter that ended in May. 2024 was 0.45.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Novo Integrated Sciences's Debt-to-Equity or its related term are showing as below:

NVOS's Debt-to-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.41
* Ranked among companies with meaningful Debt-to-Equity only.

Novo Integrated Sciences  (OTCPK:NVOS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Novo Integrated Sciences Debt-to-Equity Related Terms

Novo Integrated Sciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Novo Integrated Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Integrated Sciences Debt-to-Equity Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.15 0.31 0.58 0.18

Novo Integrated Sciences Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.18 0.20 0.24 0.45

NVOS vs BACK, NHLG, FCHS: Debt-to-Equity Comparison

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences Debt-to-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Debt-to-Equity falls into.


NVOS
12GF Score
Novo Integrated Sciences Inc NVOS
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Integrated Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Novo Integrated Sciences's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.713 + 1.759) / 24.816
=0.18

Novo Integrated Sciences's Debt to Equity Ratio for the quarter that ended in May. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.904 + 1.598) / 9.956
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.45 mean?
Novo Integrated Sciences (NVOS) has a Debt-to-Equity of 0.45 as of May. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Novo Integrated Sciences and its competitors.
Is Novo Integrated Sciences' Debt-to-Equity too high?
Novo Integrated Sciences' current Debt-to-Equity is 0.45. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Novo Integrated Sciences' value of 0.45 is 9.8% above this industry median. Overall, Novo Integrated Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novo Integrated Sciences' Debt-to-Equity compare to BACK and NHLG?
Novo Integrated Sciences' Debt-to-Equity of 0.45 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-Equity is 0.41. Novo Integrated Sciences' value of 0.45 is 9.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Integrated Sciences's current Debt-to-Equity of 0.45 is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Novo Integrated Sciences and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Integrated Sciences's current Debt-to-Equity is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Integrated Sciences stock overvalued right now?
Novo Integrated Sciences (NVOS) has a current Debt-to-Equity of 0.45. The current Debt-to-Equity is 0.45 and 9.8% above the Healthcare Providers & Services industry median of 0.41. Novo Integrated Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Novo Integrated Sciences (NVOS), the current Debt-to-Equity is 0.45 as of May. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novo Integrated Sciences Business Description

Address 11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.
12GF Score

Get the complete analysis for NVOS

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price